Sanofi Reports meta-analysis Data for Lisocabtagene maraleucel in Obesity

Sanofi today announced meta-analysis results for lisocabtagene maraleucel in patients with obesity. The study demonstrated that lisocabtagene maraleucel demonstrates sustained efficacy compared to standard of care or placebo. These results provide important insights into the treatment of obesity and support the continued development of lisocabtagene maraleucel in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.